Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

BACKGROUND: Cisplatin is the most commonly used chemotherapeutic agent in the treatment of patients with metastatic and/or recurrent urothelial cancer. However, the effectiveness of these treatments is severely limited due to the development of cisplatin resistance. Cancer stem cells have been docum...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Masayuki, Kikuchi, Eiji, Tanaka, Nobuyuki, Kosaka, Takeo, Mikami, Shuji, Saya, Hideyuki, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793458/
https://www.ncbi.nlm.nih.gov/pubmed/29385995
http://dx.doi.org/10.1186/s12885-018-3988-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793458/
https://www.ncbi.nlm.nih.gov/pubmed/29385995
http://dx.doi.org/10.1186/s12885-018-3988-3

Ejemplares similares